---
figid: PMC8096095__pone.0250649.g005
figtitle: SRI-21979 alters the expression of transcripts involved in cAMP signaling
  and apoptosis
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC8096095
filename: pone.0250649.g005.jpg
figlink: /pmc/articles/PMC8096095/figure/pone.0250649.g005/
number: F5
caption: Pathway analysis of transcripts upregulated in cAMP signaling (A) and apoptosis
  (B), following treatment with SRI021979. Light red genes are a fold change >1, while
  blue indicates a fold change of <1. Dark red genes are those with a fold change
  >5. Transcripts shown in white, do not display any change between control and treatment
  groups.
papertitle: Novel dopamine receptor 3 antagonists inhibit the growth of primary and
  temozolomide resistant glioblastoma cells.
reftext: Sarah E. Williford, et al. PLoS One. 2021;16(5):e0250649.
year: '2021'
doi: 10.1371/journal.pone.0250649
journal_title: PLoS ONE
journal_nlm_ta: PLoS One
publisher_name: Public Library of Science
keywords: ''
automl_pathway: 0.9198892
figid_alias: PMC8096095__F5
figtype: Figure
redirect_from: /figures/PMC8096095__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8096095__pone.0250649.g005.html
  '@type': Dataset
  description: Pathway analysis of transcripts upregulated in cAMP signaling (A) and
    apoptosis (B), following treatment with SRI021979. Light red genes are a fold
    change >1, while blue indicates a fold change of <1. Dark red genes are those
    with a fold change >5. Transcripts shown in white, do not display any change between
    control and treatment groups.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FASLG
  - TNF
  - ABCC4
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - ADCY3
  - ADCY8
  - UBD
  - ADORA1
  - FAS
  - FASN
  - GNAS
  - GNA12
  - DAXX
  - FADD
  - RP1
  - STK19
  - MAPRE2
  - TMEM184B-AS1
  - CALM1
  - CALM3
  - ATP8A2
  - APRT
  - MFAP1
  - FXYD1
  - ANK1
  - ANKH
  - CTSB
  - CTSL
  - TRAF2
  - TANK
  - PRKACA
  - PRKCA
  - RAPGEF3
  - RAPGEF4
  - ATM
  - DDIT3
  - BAAT
  - EIF2AK3
  - BCL2L1
  - BCL2
  - PMAIP1
  - RAP1A
  - RABGEF1
  - TERF2IP
  - RAP1B
  - CUX1
  - CYTIP
  - CRTAP
  - CASP10
  - BAK1
  - CAPN1
  - CAPN10
  - CAPN11
  - CAPN12
  - CAPN13
  - CAPN14
  - CAPN2
  - CAPN3
  - CAPN5
  - CAPN6
  - CAPN7
  - CAPN9
  - CAPN15
  - CAPN8
  - OPRM1
  - NLN
  - OPN4
  - BBC3
  - APEX1
  - TEAD1
  - TFPI2
  - TIAM1
  - TIAM2
  - VAV2
  - PPP1R1B
  - ARAP3
  - PIK3CG
  - MAP2K2
  - CASP3
  - CASP7
  - CASP2
  - PIDD1
  - RAC1
  - RNASE1
  - ENDOG
  - CREBBP
  - EIF4E
  - OPN1LW
  - PAG1
  - PCBP4
  - RHOA
  - MAPK3
  - CREB3
  - CREB3L4
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - SOX9
  - PAK1
  - PKN1
  - RHO
  - RHOD
  - RHOB
  - RHOC
  - NT5C1A
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - FOSL1
  - FOSL2
  - BAD
  - AMH
  - MCL1
  - LMNA
  - NR1I2
  - JTB
  - FANCB
  - TP53
  - BAX
  - HRK
  - ELDR
---
